Joincare Pharmaceutical Group Industry Co.,Ltd. Logo

Joincare Pharmaceutical Group Industry Co.,Ltd.

600380.SS

(3.0)
Stock Price

11,48 CNY

4.05% ROA

10.09% ROE

16.19x PER

Market Cap.

22.790.272.000,00 CNY

46.05% DER

1.48% Yield

8.77% NPM

Joincare Pharmaceutical Group Industry Co.,Ltd. Stock Analysis

Joincare Pharmaceutical Group Industry Co.,Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Joincare Pharmaceutical Group Industry Co.,Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (22.69%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 DER

The stock has a minimal amount of debt (44%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

5 ROA

The stock's ROA (8.45%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 PBV

The stock's PBV ratio (1.76x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

7 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

8 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (63) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Joincare Pharmaceutical Group Industry Co.,Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Joincare Pharmaceutical Group Industry Co.,Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Joincare Pharmaceutical Group Industry Co.,Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Joincare Pharmaceutical Group Industry Co.,Ltd. Revenue
Year Revenue Growth
1997 316.545.746
1998 390.529.638 18.94%
1999 487.466.411 19.89%
2000 677.752.172 28.08%
2001 678.817.966 0.16%
2002 711.647.636 4.61%
2003 1.752.426.088 59.39%
2004 2.345.798.357 25.3%
2005 2.488.918.119 5.75%
2006 2.076.203.679 -19.88%
2007 2.498.556.727 16.9%
2008 2.938.487.360 14.97%
2009 3.683.247.060 20.22%
2010 4.472.857.598 17.65%
2011 4.791.513.530 6.65%
2012 5.849.960.920 18.09%
2013 6.219.885.201 5.95%
2014 7.417.906.235 16.15%
2015 8.641.891.376 14.16%
2016 9.721.544.239 11.11%
2017 10.779.258.187 9.81%
2018 11.203.963.989 3.79%
2019 11.980.153.109 6.48%
2020 13.521.605.768 11.4%
2021 15.903.688.266 14.98%
2022 17.142.753.068 7.23%
2023 15.726.063.149 -9.01%
2023 16.443.141.228 4.36%
2024 15.390.145.628 -6.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Joincare Pharmaceutical Group Industry Co.,Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 301.914.946 100%
2013 186.353.539 -62.01%
2014 234.313.994 20.47%
2015 299.986.703 21.89%
2016 383.344.300 21.74%
2017 528.161.738 27.42%
2018 708.444.119 25.45%
2019 905.590.902 21.77%
2020 1.071.711.981 15.5%
2021 1.397.131.273 23.29%
2022 1.742.088.079 19.8%
2023 1.785.721.227 2.44%
2023 1.244.615.773 -43.48%
2024 1.185.370.736 -5%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Joincare Pharmaceutical Group Industry Co.,Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 21.863.873
1998 43.169.827 49.35%
1999 40.724.551 -6%
2000 52.602.403 22.58%
2001 59.567.493 11.69%
2002 74.811.485 20.38%
2003 239.280.282 68.73%
2004 336.279.108 28.84%
2005 442.129.266 23.94%
2006 362.461.206 -21.98%
2007 335.710.277 -7.97%
2008 326.622.985 -2.78%
2009 390.199.061 16.29%
2010 451.406.959 13.56%
2011 484.205.429 6.77%
2012 559.612.372 13.47%
2013 198.173.227 -182.39%
2014 179.685.190 -10.29%
2015 244.783.026 26.59%
2016 265.320.798 7.74%
2017 314.412.433 15.61%
2018 323.460.921 2.8%
2019 337.114.522 4.05%
2020 363.160.848 7.17%
2021 293.661.923 -23.67%
2022 220.293.345 -33.3%
2023 2.228.481.907 90.11%
2023 279.439.738 -697.48%
2024 -634.551.343 144.04%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Joincare Pharmaceutical Group Industry Co.,Ltd. EBITDA
Year EBITDA Growth
1997 70.589.414
1998 72.341.328 2.42%
1999 70.238.469 -2.99%
2000 229.616.035 69.41%
2001 263.502.862 12.86%
2002 257.746.780 -2.23%
2003 332.292.611 22.43%
2004 333.277.949 0.3%
2005 366.717.386 9.12%
2006 262.759.277 -39.56%
2007 1.133.894.223 76.83%
2008 998.103.641 -13.6%
2009 913.520.005 -9.26%
2010 1.377.938.023 33.7%
2011 983.930.147 -40.04%
2012 1.052.689.767 6.53%
2013 1.216.846.815 13.49%
2014 1.407.341.755 13.54%
2015 1.726.496.365 18.49%
2016 2.009.669.352 14.09%
2017 6.540.212.668 69.27%
2018 2.471.521.403 -164.62%
2019 2.821.817.183 12.41%
2020 3.611.245.585 21.86%
2021 3.733.355.596 3.27%
2022 4.655.930.859 19.82%
2023 3.455.927.990 -34.72%
2023 4.278.529.720 19.23%
2024 4.213.627.440 -1.54%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Joincare Pharmaceutical Group Industry Co.,Ltd. Gross Profit
Year Gross Profit Growth
1997 228.266.245
1998 292.610.987 21.99%
1999 353.589.161 17.25%
2000 494.421.661 28.48%
2001 491.207.120 -0.65%
2002 525.850.841 6.59%
2003 1.079.324.572 51.28%
2004 1.325.463.211 18.57%
2005 1.328.966.970 0.26%
2006 1.086.523.339 -22.31%
2007 1.249.839.113 13.07%
2008 1.498.386.903 16.59%
2009 2.048.454.299 26.85%
2010 2.566.361.969 20.18%
2011 2.535.717.703 -1.21%
2012 3.026.506.690 16.22%
2013 3.756.611.261 19.44%
2014 4.381.896.313 14.27%
2015 5.214.974.805 15.97%
2016 6.059.580.828 13.94%
2017 6.771.143.165 10.51%
2018 6.989.813.444 3.13%
2019 7.709.435.682 9.33%
2020 8.647.418.870 10.85%
2021 10.187.394.379 15.12%
2022 10.890.487.760 6.46%
2023 9.473.389.090 -14.96%
2023 9.592.238.456 1.24%
2024 9.361.101.492 -2.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Joincare Pharmaceutical Group Industry Co.,Ltd. Net Profit
Year Net Profit Growth
1997 84.806.030
1998 58.614.335 -44.68%
1999 53.250.371 -10.07%
2000 164.790.597 67.69%
2001 200.618.059 17.86%
2002 171.882.009 -16.72%
2003 140.275.065 -22.53%
2004 97.263.412 -44.22%
2005 128.009.042 24.02%
2006 -77.440.574 265.3%
2007 725.072.484 110.68%
2008 -26.956.929 2789.74%
2009 486.007.539 105.55%
2010 740.046.667 34.33%
2011 261.953.124 -182.51%
2012 169.521.951 -54.52%
2013 273.624.524 38.05%
2014 354.238.756 22.76%
2015 412.469.700 14.12%
2016 451.415.199 8.63%
2017 2.133.040.434 78.84%
2018 699.410.855 -204.98%
2019 1.850.018.010 62.19%
2020 2.578.466.495 28.25%
2021 2.612.849.038 1.32%
2022 2.894.096.096 9.72%
2023 1.072.857.679 -169.76%
2023 1.442.779.722 25.64%
2024 1.346.505.440 -7.15%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Joincare Pharmaceutical Group Industry Co.,Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 1 100%
2018 0 0%
2019 1 0%
2020 1 100%
2021 1 0%
2022 2 0%
2023 0 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Joincare Pharmaceutical Group Industry Co.,Ltd. Free Cashflow
Year Free Cashflow Growth
1999 60.661.247
2000 102.142.798 40.61%
2001 154.236.582 33.78%
2002 144.036.007 -7.08%
2003 61.644.491 -133.66%
2004 21.804.954 -182.71%
2005 -4.599.349 574.09%
2006 -217.694.540 97.89%
2007 182.634.277 219.2%
2008 237.307.868 23.04%
2009 298.791.914 20.58%
2010 520.794.417 42.63%
2011 210.241.381 -147.71%
2012 -129.121.321 262.82%
2013 -348.314.022 62.93%
2014 162.482.528 314.37%
2015 670.255.296 75.76%
2016 1.144.569.537 41.44%
2017 1.389.698.938 17.64%
2018 1.170.520.076 -18.72%
2019 1.609.249.360 27.26%
2020 2.194.591.236 26.67%
2021 1.041.669.752 -110.68%
2022 2.829.872.883 63.19%
2023 990.836.546 -185.6%
2023 2.952.078.244 66.44%
2024 479.931.056 -515.1%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Joincare Pharmaceutical Group Industry Co.,Ltd. Operating Cashflow
Year Operating Cashflow Growth
1999 109.816.146
2000 171.605.108 36.01%
2001 223.788.778 23.32%
2002 236.127.010 5.23%
2003 172.246.230 -37.09%
2004 241.705.413 28.74%
2005 363.129.421 33.44%
2006 272.498.706 -33.26%
2007 429.263.438 36.52%
2008 455.013.618 5.66%
2009 605.663.104 24.87%
2010 1.105.268.466 45.2%
2011 650.356.523 -69.95%
2012 734.362.616 11.44%
2013 635.518.849 -15.55%
2014 979.456.226 35.12%
2015 1.264.582.833 22.55%
2016 1.644.557.267 23.1%
2017 1.870.376.097 12.07%
2018 1.825.535.799 -2.46%
2019 2.312.447.687 21.06%
2020 3.024.999.592 23.56%
2021 2.563.089.045 -18.02%
2022 3.977.705.139 35.56%
2023 1.202.644.059 -230.75%
2023 4.082.226.745 70.54%
2024 766.186.053 -432.8%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Joincare Pharmaceutical Group Industry Co.,Ltd. Capital Expenditure
Year Capital Expenditure Growth
1999 49.154.899
2000 69.462.309 29.24%
2001 69.552.195 0.13%
2002 92.091.003 24.47%
2003 110.601.738 16.74%
2004 219.900.459 49.7%
2005 367.728.770 40.2%
2006 490.193.246 24.98%
2007 246.629.160 -98.76%
2008 217.705.749 -13.29%
2009 306.871.189 29.06%
2010 584.474.049 47.5%
2011 440.115.142 -32.8%
2012 863.483.937 49.03%
2013 983.832.871 12.23%
2014 816.973.697 -20.42%
2015 594.327.536 -37.46%
2016 499.987.729 -18.87%
2017 480.677.158 -4.02%
2018 655.015.722 26.62%
2019 703.198.326 6.85%
2020 830.408.355 15.32%
2021 1.521.419.293 45.42%
2022 1.147.832.255 -32.55%
2023 211.807.513 -441.92%
2023 1.130.148.501 81.26%
2024 286.254.997 -294.8%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Joincare Pharmaceutical Group Industry Co.,Ltd. Equity
Year Equity Growth
1997 109.789.518
1998 140.593.834 21.91%
1999 189.891.487 25.96%
2000 257.747.095 26.33%
2001 1.981.154.228 86.99%
2002 2.011.796.577 1.52%
2003 3.032.415.836 33.66%
2004 2.972.519.073 -2.02%
2005 3.028.231.062 1.84%
2006 2.882.084.397 -5.07%
2007 4.070.471.294 29.2%
2008 3.861.782.739 -5.4%
2009 4.401.815.570 12.27%
2010 5.317.038.611 17.21%
2011 5.459.773.970 2.61%
2012 5.590.746.726 2.34%
2013 6.024.314.158 7.2%
2014 6.541.515.693 7.91%
2015 7.307.120.915 10.48%
2016 9.334.755.958 21.72%
2017 13.617.850.127 31.45%
2018 16.297.034.008 16.44%
2019 17.384.026.250 6.25%
2020 19.236.898.076 9.63%
2021 20.179.610.978 4.67%
2022 22.020.227.697 8.36%
2023 22.639.530.490 2.74%
2023 22.093.595.345 -2.47%
2024 23.113.627.134 4.41%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Joincare Pharmaceutical Group Industry Co.,Ltd. Assets
Year Assets Growth
1997 448.724.520
1998 593.192.349 24.35%
1999 682.035.772 13.03%
2000 759.520.278 10.2%
2001 2.327.350.377 67.37%
2002 2.523.199.897 7.76%
2003 4.415.827.026 42.86%
2004 4.413.648.169 -0.05%
2005 4.391.971.331 -0.49%
2006 4.745.721.257 7.45%
2007 6.014.386.259 21.09%
2008 5.821.348.151 -3.32%
2009 6.145.975.061 5.28%
2010 7.107.733.295 13.53%
2011 8.814.292.181 19.36%
2012 9.754.159.425 9.64%
2013 10.745.325.112 9.22%
2014 12.084.314.377 11.08%
2015 13.795.581.594 12.4%
2016 16.071.712.257 14.16%
2017 22.211.585.894 27.64%
2018 24.985.756.544 11.1%
2019 25.437.613.001 1.78%
2020 28.156.977.599 9.66%
2021 31.103.900.389 9.47%
2022 35.729.253.651 12.95%
2023 36.358.126.258 1.73%
2023 35.769.669.256 -1.65%
2024 36.496.077.306 1.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Joincare Pharmaceutical Group Industry Co.,Ltd. Liabilities
Year Liabilities Growth
1997 338.935.002
1998 452.598.514 25.11%
1999 492.144.285 8.04%
2000 501.773.182 1.92%
2001 346.196.148 -44.94%
2002 511.403.319 32.3%
2003 1.383.411.189 63.03%
2004 1.441.129.094 4.01%
2005 1.363.740.268 -5.67%
2006 1.863.636.858 26.82%
2007 1.943.914.963 4.13%
2008 1.959.565.411 0.8%
2009 1.744.159.490 -12.35%
2010 1.790.694.683 2.6%
2011 3.354.518.210 46.62%
2012 4.163.412.699 19.43%
2013 4.721.010.952 11.81%
2014 5.542.798.683 14.83%
2015 6.488.460.678 14.57%
2016 6.736.956.298 3.69%
2017 8.593.735.766 21.61%
2018 8.688.722.535 1.09%
2019 8.053.586.750 -7.89%
2020 8.920.079.522 9.71%
2021 10.924.289.409 18.35%
2022 13.709.025.953 20.31%
2023 13.348.416.217 -2.7%
2023 13.676.073.911 2.4%
2024 13.028.411.715 -4.97%

Joincare Pharmaceutical Group Industry Co.,Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.57
Net Income per Share
0.75
Price to Earning Ratio
16.19x
Price To Sales Ratio
1.42x
POCF Ratio
5.05
PFCF Ratio
6.75
Price to Book Ratio
1.59
EV to Sales
0.88
EV Over EBITDA
3.66
EV to Operating CashFlow
3.14
EV to FreeCashFlow
4.19
Earnings Yield
0.06
FreeCashFlow Yield
0.15
Market Cap
22,79 Bil.
Enterprise Value
14,13 Bil.
Graham Number
11.38
Graham NetNet
4.14

Income Statement Metrics

Net Income per Share
0.75
Income Quality
3.21
ROE
0.1
Return On Assets
0.04
Return On Capital Employed
0.12
Net Income per EBT
0.41
EBT Per Ebit
1.12
Ebit per Revenue
0.19
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.61
Operating Profit Margin
0.19
Pretax Profit Margin
0.22
Net Profit Margin
0.09

Dividends

Dividend Yield
0.01
Dividend Yield %
1.48
Payout Ratio
0.65
Dividend Per Share
0.18

Operating Metrics

Operating Cashflow per Share
2.41
Free CashFlow per Share
1.81
Capex to Operating CashFlow
0.25
Capex to Revenue
0.07
Capex to Depreciation
1.16
Return on Invested Capital
0.12
Return on Tangible Assets
0.04
Days Sales Outstanding
113.43
Days Payables Outstanding
46.27
Days of Inventory on Hand
152.04
Receivables Turnover
3.22
Payables Turnover
7.89
Inventory Turnover
2.4
Capex per Share
0.6

Balance Sheet

Cash per Share
8,41
Book Value per Share
12,56
Tangible Book Value per Share
11.57
Shareholders Equity per Share
7.66
Interest Debt per Share
3.61
Debt to Equity
0.46
Debt to Assets
0.18
Net Debt to EBITDA
-2.24
Current Ratio
2.12
Tangible Asset Value
21,63 Bil.
Net Current Asset Value
10,57 Bil.
Invested Capital
20905373169
Working Capital
12,48 Bil.
Intangibles to Total Assets
0.05
Average Receivables
4,91 Bil.
Average Payables
0,81 Bil.
Average Inventory
2604188235
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Joincare Pharmaceutical Group Industry Co.,Ltd. Dividends
Year Dividends Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2008 0 0%
2009 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Joincare Pharmaceutical Group Industry Co.,Ltd. Profile

About Joincare Pharmaceutical Group Industry Co.,Ltd.

Joincare Pharmaceutical Group Industry Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and healthcare products primarily in China. The company offers chemical drug preparation products, including respiration, gastroenterology, anti-infection, gonadotropic, and psychiatric products; and traditional chinese drug preparation production, which includes anti-tumor and cold products. It also provides chemical APIs and intermediates; diagnostic reagents and equipment, including autoimmunity multiple detection platform and diagnostic kit for IgM; and healthcare products, which includes American ginseng tea and Jingxin menocare essence. In addition, the company engages in the wholesale and retail of skin care products, cosmetics, and other necessities. It offers its products in various forms, such as hormone tablets, oral liquids, and tablets. The company was founded in 1992 and is headquartered in Shenzhen, China.

CEO
Mr. Xiong Yu
Employee
14.365
Address
Joincare Pharmaceutical Group Building
Shenzhen, 518057

Joincare Pharmaceutical Group Industry Co.,Ltd. Executives & BODs

Joincare Pharmaceutical Group Industry Co.,Ltd. Executives & BODs
# Name Age
1 Mr. Feng Guang Zhao
Vice President & Secretary of the Board of Directors
70
2 Mr. Leiming Zhang
Vice President
70
3 Mr. Nanqi Lin
Vice President & Director
70
4 Lingzhi Tang
Financial Controller
70
5 Mr. Xiong Yu
President & Director
70
6 Mr. Qingfeng Qiu
Vice President, Chief Financial Officer & Director
70

Joincare Pharmaceutical Group Industry Co.,Ltd. Competitors